Myasthenia Gravis
📧 Sign up to get email alerts when something new happens for Myasthenia Gravis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety, tolerability, pharmacodynamics and efficacy of CNP-106 in subjects with Myasthenia gravis …
-
CLINICAL_TRIALS other · 2025-02-03Clinical Trial Update: Dixon MRI Imaging Histology for Predicting Postoperative Infection in Posterior Lumbar Fusion for Myasthenia Gravis
The trial investigates Dixon MRI imaging histology and radiomics to predict postoperative infection after posterior lumbar fusion in patient…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University Hospitals
This entry describes a clinical and laboratory profile study of myasthenia gravis in children at Sohag University Hospitals, currently not y…
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis [Phase 2]
The Phase 2 trial of ALXN2050 in adults with generalized myasthenia gravis was terminated. Results from the study have been posted.
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. [EARLY_Phase 1]
A Phase 1 trial evaluating universal CAR-T cells for refractory autoimmune diseases of the nervous system; the study is not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Pilot Study: Use of the Saccadometer to Detect Characteristic Saccadic Peak Velocity in Myasthenia Gravis Patients [NA]
This completed pilot study evaluated whether the Saccadometer can detect characteristic saccadic peak velocity in patients with Myasthenia G…
-
CLINICAL_TRIALS research · 2024-12-10Clinical Trial Update: Exploring Outcomes and Characteristics of Myasthenia Gravis 2
Clinical trial update describing a Yale University study exploring outcomes and characteristics of Myasthenia Gravis; the trial is currently…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis [Phase 4]
A Phase 4 study is evaluating Telitacicept plus low-dose corticosteroids for refractory Myasthenia Gravis; the trial status is not yet recru…
-
CLINICAL_TRIALS trial_result · 2024-11-27Clinical Trial Update: Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
An update on an active, not-recruiting clinical study evaluating diaphragmatic ultrasound for prognostic outcomes in myasthenia gravis. The …
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Biomarkers in Autoimmune Disease of Nervous System
A Tongji Hospital clinical trial is recruiting to study biomarkers in autoimmune diseases of the nervous system, including Neuromyelitis Opt…
-
CLINICAL_TRIALS research · 2024-11-14Clinical Trial Update: Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis [Phase 4]
Phase 4 clinical trial evaluating intravenous efgartigimod for myasthenic crisis; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) [Phase 2, Phase 3]
A Phase 2/3 clinical trial is evaluating blinatumomab for refractory myasthenia gravis, with recruitment not yet started.
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System [EARLY_Phase 1]
An early-phase clinical trial is investigating CT103A cell therapy for relapsed/refractory antibody-associated inflammatory diseases of the …
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis [Phase 3]
A Phase 3 study evaluating rituximab for generalized myasthenia gravis has completed and results have been posted.
-
FDA approval · 2024-10-25FDA Approved: NEOSTIGMINE METHYLSULFATE — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for Neostigmine Methylsulfate submitted by Eugia US LLC.
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Interval Inspiratory Training and Aerobic Exercise for Muscle Recovery in Myasthenia Gravis Post-Hospitalization [NA]
A completed clinical trial evaluated interval inspiratory training and aerobic exercise for muscle recovery in myasthenia gravis after hospi…
-
CLINICAL_TRIALS research · 2024-10-10Clinical Trial Update: Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis
A study comparing the sensitivity of repetitive nerve stimulation performed in the evening versus the morning in patients with Myasthenia Gr…
-
FDA approval · 2024-10-04FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Surgeon General-Department of the Army (TSG-DA))
The FDA approved a supplemental application for pyridostigmine bromide, with involvement of the Surgeon General-Department of the Army, upda…
-
FDA approval · 2024-10-04FDA Approved: PYRIDOSTIGMINE BROMIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved pyridostigmine bromide from Amneal Pharmaceuticals under an original application for use in treating myasthenia gravis.
-
CLINICAL_TRIALS research · 2024-09-27Clinical Trial Update: Myasthenia Gravis Foundation of America Global MG Patient Registry
Global MG patient registry study led by the Myasthenia Gravis Foundation of America is seeking to enroll patients worldwide. The registry is…
-
FDA approval · 2024-09-19FDA Approved: SOLIRIS — Supplemental Application (Alexion Pharmaceuticals Inc.)
The FDA approved a supplemental application for SOLIRIS (eculizumab) filed by Alexion Pharmaceuticals, resulting in updated labeling that ma…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: The Risk of Falls Index for Patients With Neuromuscular Disorders
A completed trial evaluating a Falls Index to assess fall risk in patients with neuromuscular disorders, including Inclusion Body Myositis, …
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Seronegative Myasthenia Gravis - Efgartigimod IV [Phase 3]
Phase 3 clinical trial update for seronegative generalized myasthenia gravis evaluating efgartigimod IV; the study is currently recruiting.
-
FDA approval · 2024-08-08FDA Approved: VYVGART — Supplemental Application (argenx US)
FDA approved a supplemental Biologics License Application for VYVGART (efgartigimod alfa) by argenx US, resulting in a label/indication upda…
-
FDA approval · 2024-08-08FDA Approved: VYVGART HYTRULO — Supplemental Application (argenx US)
The FDA approved a supplemental application for Vyvgart Hytrulo, a combination of efgartigimod alfa and recombinant hyaluronidase, submitted…